Clinical TrialMay 11, 2026, 07:02 AM
Alpha Tau reports 67% complete response in GBM trial; 100% disease control
AI Summary
Alpha Tau Medical Ltd. announced groundbreaking positive interim results from its U.S. Alpha DaRT REGAIN trial for patients with recurrent glioblastoma (GBM). Out of three patients treated, two achieved a complete response with total disappearance of tumor lesions, and one demonstrated stable disease with a 30% tumor decrease, leading to 100% local disease control and a 67% complete response rate. The trial also reported a favorable safety profile, with only one resolved grade 3 serious adverse event and no unanticipated issues.
Key Highlights
- Alpha Tau reported positive interim results from its U.S. Alpha DaRT REGAIN trial for recurrent glioblastoma (GBM).
- Two out of three patients treated demonstrated a continued complete response, with total disappearance of tumor lesions.
- The third patient showed stable disease with a 30% decrease in tumor dimension.
- The trial achieved 100% local disease control and a 67% complete response rate across the initial patient cohort.
- Only one grade 3 serious adverse event (seizure with temporary paralysis) was observed, which resolved.
- No unanticipated serious adverse events, local or distant recurrence, or residual symptoms were observed.
- A conference call with management and the principal investigator is scheduled for May 11, 2026.